Inotiv, Inc. to Report First Quarter Fiscal 2022 Financial Results and Host Conference Call on Thursday, February 10, 2022
Inotiv, Inc. (NASDAQ: NOTV) will release its financial results for the fiscal 2022 first quarter, ending December 31, 2021, on February 10, 2022, after market close. The Company will host a conference call at 4:30 p.m. ET on the same day for discussion of the results. Interested participants can join via domestic and international dialing options. The live webcast will be accessible on the Investors section of Inotiv's website, with a replay available post-broadcast. Inotiv specializes in drug discovery and development services, focusing on improving efficiency and reducing costs in bringing new drugs to market.
- None.
- None.
WEST LAFAYETTE, Ind., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that the Company will issue its financial results press release for the fiscal 2022 first quarter ended December 31, 2021, on Thursday, February 10, 2022, after the close of the stock market and host a conference call the same day at 4:30 p.m. Eastern Time to discuss the results.
Interested parties may participate in the call by dialing:
- (877) 407-9753 (Domestic)
- (201) 493-6739 (International)
The live conference call webcast will be accessible in the Investors section of the Company’s web site and directly via the following link:
https://themediaframe.com/mediaframe/webcast.html?webcastid=cXkN5tYP
For those who cannot listen to the live broadcast, an online replay will be available in the Investors section of Inotiv’s web site at: https://www.inotivco.com/investors/investor-information/.
About the Company
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: https://www.inotivco.com/.
This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, the impact of the COVID-19 pandemic on the economy, demand for our services and products and our operations, including the measures taken by governmental authorities to address the pandemic, which may precipitate or exacerbate other risks and/or uncertainties, expansion and related efforts, and various other market and operating risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
| Company Contact | Investor Relations | |
| Inotiv, Inc. | The Equity Group Inc. | |
| Beth A. Taylor, Chief Financial Officer | Kalle Ahl, CFA | |
| (765) 497-8381 | (212) 836-9614 | |
| btaylor@inotivco.com | kahl@equityny.com | |
| Devin Sullivan | ||
| (212) 836-9608 | ||
| dsullivan@equityny.com |
FAQ
When will Inotiv, Inc. release its Q1 2022 financial results?
What time is the conference call for Inotiv's Q1 2022 earnings?
How can I participate in Inotiv's Q1 2022 earnings call?
Where can I find the webcast for Inotiv's Q1 earnings call?
